ROTARIX, rotavirus vaccines
INFECTIOLOGY - NEW MEDICINAL PRODUCT
Opinions on drugs -
Posted on
Jun 08 2015
Reason for request
Inclusion
- ROTARIX and ROTATEQ are live attenuated oral vaccines with Marketing Authorisation since 2006 in the prevention of acute gastroenteritis due to rotavirus infection (RV-AGE) in infants.
- The efficacy of these vaccines is high, but the most recent safety data confirm an increased risk of acute intussusception (AI) estimated at about 6 additional cases per 100,000 vaccinated individuals.
- In view of the risk of AI and given the epidemiology of RV-AGE in France, rotavirus vaccination is not expected to impact on public health if vaccine coverage is low.
Clinical Benefit
Insufficient |
- |
Therapeutic use
- |
-
Economic analysis
English version
Contact Us
Évaluation des médicaments